Clinical Trials Logo
  1. Home
  2. Pain, Intractable
  3. NCT00216684

Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics

Pain, Intractable Clinical Trial

Official title:
An Open Label Study to Confirm the Effectiveness, and Safety of Fentanyl Transdermal Matrix Patch in Japanese Patients With Chronic Intractable Pain Who Has Prior Therapy of Codeine, Morphine Hydrochloride, or Fentanyl Injectable Preparations.

Clinical Trial Summary

The purpose of this study is to verify the effectiveness, and safety in Japanese patients with chronic intractable pain after 4-week medication of fentanyl transdermal matrix patches containing either 12.5 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, or 100 mcg/hr, who have been switched from existing formulations, such as codeine, morphine hydrochloride, or fentanyl injectable. Furthermore, the safety and effectiveness of long term treatment such as 48 weeks are to be assessed, if possible.

Clinical Trial Description

Fentanyl transdermal matrix patch is a narcotic analgesic agent. Compared with the existing reservoir-type Durotep® Patch, fentanyl transdermal matrix patch is not liable to leakage of drug solution and does not contain alcohol, which becomes a cause of skin irritation. Also this new formulation has become available in a smaller dose of 12.5mg/hr while the smallest Durotep® Patch is 25mg/hr. While Durotep® Patch is currently indicated only for cancer pain in Japan, this clinical trial was planned to assess effectiveness, and safety of fentanyl transdermal matrix patch in Japanese patients with chronic intractable pain receiving codeine, morphine hydrochloride, or fentanyl injectable formulations. After pre-treatment period for seven to fourteen days for evaluating the eligibility of the patients for the study, patients will be treated for 4 weeks as Treatment period 1 and 48 weeks as Treatment period 2 followed by 3-day post-treatment observation period. One patch can be used for 72 hours, which is the same as the existing Patch. Starting from the first day of treatment, fentanyl will be applied to the chest, the upper arm or other appropriate site, which will be replaced with a new patch every three days (ca. 72 hr). Starting dose should be between 12.5 mcg/hr and 75 mcg/hr, depending on the prior opioid dose. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00216684
Study type Interventional
Source Janssen Pharmaceutical K.K.
Contact
Status Completed
Phase Phase 3
Start date May 2005
Completion date September 2006
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03887494 - Study of the Impact of the Femoral Implant "Y-strut" on Lytic Bone Metastases of the Femoral Neck (WAZA-ARY) N/A
Recruiting NCT05761392 - APP-based Precise Management System of Chronic Intractable Pain N/A
Suspended NCT05067257 - Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer Phase 2
Enrolling by invitation NCT02485795 - Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management N/A
Withdrawn NCT01951911 - Effectiveness of Ketamine in Malignant Neuropathic Pain Relief Phase 3
Completed NCT04701008 - Efficacy of Ketamine in Post Anesthesia Recovery Room
Completed NCT03350256 - BurstDR™ micrOdosing stimuLation in De-novo Patients N/A
Completed NCT04602286 - How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Pain Sample) N/A
Completed NCT04625504 - Investigating Biological Targets, Markers, and Intervention for Chronic Pain N/A
Recruiting NCT05398003 - Medullary Stimulation for the Treatment of Refractory Neck Pain (S2M) N/A
Completed NCT02886286 - Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain Phase 4
Recruiting NCT05775510 - Study to Evaluate Neuromodulation Subject Experience With Contemporary Spinal Cord Stimulation (SCS) Modalities for Chronic Pain
Active, not recruiting NCT04727216 - Intermittent vs. Continuous Dorsal Root Ganglion Stimulation N/A
Completed NCT02091076 - Efficacy and Safety of Silk Fibroin With Bioactive Coating Layer Dressing Phase 1/Phase 2
Completed NCT01166906 - Pain Blocking During Drug Administration or Blood Collection With Needles
Recruiting NCT04876469 - Radiocontrast Media in the Pulsed Radiofrequency Treatment N/A
Completed NCT05108103 - Determination of Longus Colli Muscle Thickness by Ultrasonography
Completed NCT04727749 - Pawsitive Impacts of Therapy Dog Visits N/A
Completed NCT04096391 - Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population N/A
Terminated NCT00122915 - CONCEPT: Crossover Efficacy Pain Trial in Motor Cortex Stimulation for Intractable Neuropathic Pain Phase 3